Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Ryan

Showing results (101-110 of 274) with videos related to

Pageof 28
Sort By:
Cancer|June 5, 2013
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumorJennifer A Chan, Lawrence Blaszkowsky, Keith Stuart, et al.
Clinical Colorectal Cancer|October 10, 2006
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancerBrian M Wolpin, Jeffrey W Clark, Jeffrey A Meyerhardt, et al.
Cancer Investigation|October 10, 2003
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancerDavid P Ryan, Jeffrey W Clark, Matthew H Kulke, et al.
Cancer Chemotherapy and Pharmacology|December 20, 2005
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumorsJoseph P Eder, David P Ryan, Leonard Appleman, et al.
Cancer Journal (Sudbury, Mass.)|November 6, 2002
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancerMatthew H Kulke, George D Demetri, Norman E Sharpless, et al.
Clinical Colorectal Cancer|March 18, 2004
Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancerAndrew X Zhu, Thomas A Puchalski, Vincent P Stanton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2013
Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimensKimmie Ng, Josep Tabernero, Jimmy Hwang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumorsLinda L Garland, Manuel Hidalgo, David S Mendelson, et al.
Archives of Surgery (Chicago, Ill. : 1960)|November 19, 2008
A randomized controlled trial to improve lymph node assessment in stage II colon cancerFrances C Wright, Anna R Gagliardi, Calvin H L Law, et al.
Pancreas|November 16, 2016
Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant TreatmentRyan D Nipp, Andrea Zanconato, Hui Zheng, et al.
Pageof 28

Showing results (101-110 of 274) with videos related to

Sort By:
Pageof 28
Cancer|June 5, 2013
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumorJennifer A Chan, Lawrence Blaszkowsky, Keith Stuart, et al.
Clinical Colorectal Cancer|October 10, 2006
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancerBrian M Wolpin, Jeffrey W Clark, Jeffrey A Meyerhardt, et al.
Cancer Investigation|October 10, 2003
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancerDavid P Ryan, Jeffrey W Clark, Matthew H Kulke, et al.
Cancer Chemotherapy and Pharmacology|December 20, 2005
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumorsJoseph P Eder, David P Ryan, Leonard Appleman, et al.
Cancer Journal (Sudbury, Mass.)|November 6, 2002
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancerMatthew H Kulke, George D Demetri, Norman E Sharpless, et al.
Clinical Colorectal Cancer|March 18, 2004
Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancerAndrew X Zhu, Thomas A Puchalski, Vincent P Stanton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2013
Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimensKimmie Ng, Josep Tabernero, Jimmy Hwang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumorsLinda L Garland, Manuel Hidalgo, David S Mendelson, et al.
Archives of Surgery (Chicago, Ill. : 1960)|November 19, 2008
A randomized controlled trial to improve lymph node assessment in stage II colon cancerFrances C Wright, Anna R Gagliardi, Calvin H L Law, et al.
Pancreas|November 16, 2016
Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant TreatmentRyan D Nipp, Andrea Zanconato, Hui Zheng, et al.
Pageof 28